Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
CNS Neurosci Ther
2012 Jun 01;186:493-500. doi: 10.1111/j.1755-5949.2012.00313.x.
Show Gene links
Show Anatomy links
Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2).
Wolff C
,
Carrington B
,
Varrin-Doyer M
,
Vandendriessche A
,
Van der Perren C
,
Famelart M
,
Gillard M
,
Foerch P
,
Rogemond V
,
Honnorat J
,
Lawson A
,
Miller K
.
???displayArticle.abstract???
AIMS: Lacosamide (LCM; SPM 927, Vimpat®) is an antiepileptic drug (AED) used as adjunctive treatment for adults with partial-onset seizures. LCM has a different mode of action from traditional sodium channel blocking AEDs in that it selectively enhances slow inactivation of sodium channels without affecting fast inactivation. Initial investigations suggested that LCM might have an additional mode of action by binding to the collapsin response mediator protein 2 (CRMP-2), which is further investigated here.
METHODS: LCM binding to native and cloned human CRMP-2 was determined using radioligand binding experiments and surface plasmon resonance measurements.
RESULTS: No specific binding of [(3) H]LCM (free concentration 100-1450 nM) to isolated or membrane bound human CRMP-2 expressed in mammalian cell systems and bacteria was observed. Surface plasmon resonance analysis also showed that LCM, over a concentration range of 0.39-100 μM, does not specifically bind to human CRMP-2.
CONCLUSION: The diverse drug binding methods employed here are well suited to detect specific binding of LCM to CRMP-2 in the micromolar range, yet the results obtained were all negative. Results of this study suggest that LCM does not specifically bind to CRMP-2.
Beyreuther,
Lacosamide: a review of preclinical properties.
2007, Pubmed
Beyreuther,
Lacosamide: a review of preclinical properties.
2007,
Pubmed
Charrier,
Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders.
2003,
Pubmed
Chi,
Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons.
2009,
Pubmed
Czech,
Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy.
2004,
Pubmed
Deo,
Structural bases for CRMP function in plexin-dependent semaphorin3A signaling.
2004,
Pubmed
Errington,
The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.
2008,
Pubmed
Hensley,
Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.
2011,
Pubmed
Karlsson,
Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities.
1995,
Pubmed
Kawano,
CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation.
2005,
Pubmed
Lynch,
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
2004,
Pubmed
Park,
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
2009,
Pubmed
Sake,
A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
2010,
Pubmed
Schmidt,
The CRMP family of proteins and their role in Sema3A signaling.
2007,
Pubmed
Sheets,
Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine.
2008,
Pubmed
Stenmark,
The structure of human collapsin response mediator protein 2, a regulator of axonal growth.
2007,
Pubmed
Takahashi,
Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors.
1999,
Pubmed
Wang,
In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.
2010,
Pubmed
Wang,
Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission.
2010,
Pubmed
Wolff,
[3H]linopirdine binding to rat brain membranes is not relevant for M-channel interaction.
2005,
Pubmed
